Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI 287 + Bevacizumab in Recurrent Glioblastoma
NCT02047214Phase 2Terminated
- Sponsor
- Cortice Biosciences Inc.
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abeotaxane in glioblastoma multiforme (GBM), sponsored by Cortice Biosciences Inc.. Started Jan 2014; status: terminated.
02
Drugs
abeotaxane
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02047214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047214.